#melanoma
Related Stories (6)
BBC Inside Science
Has a personalised cancer vaccine become reality?
August 20, 2026Vaccine breakthrough stops cancer returning in trial
A new jab extended the length of time patients were cancer free, but it is unclear for how long.
August 19, 2026VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results Reuters
August 19, 2026Moderna shares surge as melanoma vaccine with Merck succeeds in large trial - reuters.com
Moderna shares surge as melanoma vaccine with Merck succeeds in large trial reuters.com
August 19, 2026Riskiest skin cancer cases hit UK record high
The number of melanoma skin cancer cases has risen above 20,000 a year for the first time in the UK.
May 21, 2026Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
April 10, 2026Related Pages (5)
Is the era of the cancer vaccine upon us?
Radio 4,·20 Aug 2026,·28 mins Available for 35 days This week Merck (known as MSD in Europe) and Moderna announced that a personalised cancer vaccine had significantly improved the outcomes of melan
Vaccine breakthrough stops cancer returning in trial
A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment. The vaccine,
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Replimune’s drug for advanced skin cancer fails to win FDA nod again
By Padmanabhan Ananthan and Sruthi Narasimha Chari April 10 (Reuters) – The U.S. Food and Drug Administration on Friday declined to approve Replimune’s drug for advanced skin cancer, citing insuffici